Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Table 6

Efficacy and safety of rivaroxaban in patients with PE combined with or without frailty.

		PE with frailty (22)	PE without frailty		value
Efficacy				-0.72	0.471
Disappeared	55	12 (54.55%)	43 (67.19%)	1.35	0.289
Effective	20	8 (36.36%)	12 (18.75%)	2.846	0.092
No effect	5	1 (4.55%)	4 (6.25%)	<0.001	1
Progressed	2	0 (0.00%)	2 (3.13%)		0.552
Bleeding				-1.363	0.173
Bleeding	39	8 (36.36%)	31 (48.44%)	0.963	0.326
Mild bleeding	27	13 (59.09%)	27 (42.19%)	1.88	0.170
Serve bleeding	1	0 (0.00%)	1 (1.56%)		0.744
Major bleeding	1	1 (4.55%)	0 (0.00%)		0.256